To The Moon

$Novavax(NVAX)$ 🚀 $NVAX, Escaping the Doom Loop? A Speculative LEAPS Play in the Making 🔥

Novavax, $NVAX, has been stuck in a brutal downtrend, battered by financial struggles, market scepticism, and relentless volatility. But is this biotech underdog finally bottoming out? The technical setup suggests a potential shift, with the stock hovering around key support levels and signs of exhaustion in selling pressure. Meanwhile, implied volatility remains lofty at 84%, signalling wild swings ahead.

I am eyeing January 2027 LEAPS as a speculative way to play what could be a long-term reversal. If NVAX regains traction, this could be a high-risk, high-reward opportunity. Let’s break it down:

🛠 The Technical Setup, Cracks in the Downtrend?

NVAX has been a poster child for volatility, peaking in 2021 before entering a prolonged selloff. But recent price action suggests a potential inflection point.

   •   Oversold Conditions The Relative Strength Index, RSI, is flashing oversold signals, hinting that downside momentum may be losing steam.

   •   Bullish Divergence A subtle divergence in volume and price action suggests selling pressure could be drying up.

   •   Short Squeeze Potential NVAX maintains significant short interest, and any sudden positive catalyst could trigger a rapid covering rally.

While these factors do not guarantee a turnaround, they make the stock worth watching.

⚡ The Volatility Factor, A Double-Edged Sword

With an implied volatility of 84%, the market expects turbulence. High IV inflates option premiums but also increases the potential for explosive moves. For long-term speculators, this presents an opportunity, if timed correctly.

📅 The Strategy, Betting on 2027 LEAPS

A January 2027 LEAPS call position offers a way to participate in a potential turnaround while managing capital exposure.

   •   Lower Strikes Show Interest Open interest in the lower strikes indicates some traders are positioning for a long-term recovery.

   •   Asymmetric Risk-Reward A relatively small investment in LEAPS could yield outsized returns if NVAX stages a comeback.

But let’s be clear, if NVAX stagnates or continues to slide, these options could expire worthless. This is a moonshot play, not a safe bet.

🚨 Catalysts, What Could Spark a Move?

NVAX’s financials are rough, negative EPS, cash burn, and debt concerns. However, biotech stocks thrive on catalysts, and NVAX has a few potential game-changers,

✅ FDA-Approved COVID-19 Vaccine, 2024-25 Season Could drive renewed interest.

✅ Strategic Partnerships and Funding A lifeline deal could shift sentiment.

✅ Short Covering Rally High short interest means any bullish surprise could force a squeeze.

Of course, competition from Moderna and Pfizer remains fierce, and without a major breakthrough, NVAX could continue its decline.

🔍 The Bottom Line, A Speculative Moonshot

This isn't a play for the faint of heart. $NVAX remains a highly volatile, high-risk stock, and betting on its turnaround with 2027 LEAPS is a calculated gamble.

   •   Best case? A major catalyst ignites a reversal, triggering a short squeeze and sending calls soaring.

   •   Worst case? The stock continues bleeding, and these options expire worthless.

For those willing to embrace the volatility, the setup is compelling. But as with all speculative plays, size your position wisely and be prepared for anything.

📢 Please Like, Repost, and Follow me for sharp setups, stock trends, and actionable insights 🚀📈 I am all about spotting the next movers and sharing strategies that deliver results! Let’s trade smarter and grow together! 🍀🍀🍀

Happy trading ahead! Cheers BC 📈🚀🍀🍀🍀

@Tiger_comments @Daily_Discussion @TigerPicks @TigerStars @TigerWire @TigerGPT